^
Association details:
| Biomarker: | ALK mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Alecensa (alectinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase IV clinical trial for alectinib as first-line treatment of advanced non-small cell lung cancer with positive ALK gene.
Excerpt:
...Patients with non-small cell lung cancer confirmed by histology or cytology and alk mutation detected; 4. ...
Trial ID:
Source:
Title:
[Clinical features of the ALK-mutant non-small cell lung cancer patients who received first-line alectinib treatment]
Excerpt:
Patients diagnosed with ALK-mutant NSCLC and received alectinib treatment as a first-line tyrosine kinase inhibitor were enrolled to study and retrospectively analyzed….The objective response rate was 78.9% with alectinib treatment….After median 9.5 months follow-up, median progression-free survival (PFS) was not achieved. 24-month PFS was 67% and 24-month overall survival was 84%.
DOI:
10.5578/tt.20219704
Source:
Title:
A Case of Advanced Non-Small-Cell Lung Cancer With Response to Alectinib and Favorable Quality of Life
Published date:
01/12/2022
Excerpt:
Here, we present the case of a 37-year-old female who was diagnosed with stage IV NSCLC (adenocarcinoma) with a positive ALK mutation six years ago...she has continued to have an excellent response to alectinib, documented with the gradual decrease in the size of the lung lesion (Figure 3) and no apparent, metabolically active disease according to positron emission tomography-CT scans. She has had an Eastern Cooperative Oncology Group Performance Status score of zero with an excellent quality of life.
DOI:
10.7759/cureus.21170
